UBS Global Biopharma Conference 2026
Logotype for Cogent Biosciences Inc

Cogent Biosciences (COGT) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Cogent Biosciences Inc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

Regulatory milestones

  • Bezuclastinib, a selective KIT mutant inhibitor, completed pivotal studies in imatinib-resistant GIST and advanced and non-advanced systemic mastocytosis; positive readouts came in 2025–2026.

  • PDUFA dates: Nov. 30, 2026 for second-line GIST; Dec. 30, 2026 for non-advanced systemic mastocytosis; June 29, 2027 for advanced systemic mastocytosis.

GIST safety and market opportunity

  • Safety database exceeds 1,000 bezuclastinib-treated people; reported effects include taste changes, white hair growth and transaminase fluctuations, generally without clinical sequelae or need for dose changes.

  • Higher-grade transaminase elevations occurred early; monthly monitoring, as used with sunitinib, was cited as a proxy, with duration guided by clinical need.

  • Management expects any black-box warning or liver monitoring to have no noticeable impact on GIST uptake; it cited sunitinib’s existing warning and monitoring as established practice.

  • Estimated 2,500–3,000 patients annually become eligible after imatinib resistance; PEAK Phase III mean treatment duration was 21.4 months at the last check.

  • Modeled U.S. opportunity is $2.5B, with potential in Europe, Japan and other markets; rare cancer drug benchmarks cited were ~$44,000–$47,000+ monthly WAC.

Non-advanced systemic mastocytosis

  • Management described bezuclastinib as selective for KIT and non-CNS-penetrant, enabling clinically relevant dosing; it contrasted this with Ayvakit’s broader kinase activity, CNS penetration and 25 mg non-advanced dose.

  • Management cited improvements in serum tryptase, mast-cell burden and variant allele frequency, and reported undetectable bone-marrow mutant mast cells in nearly two-thirds of patients at six months.

  • Symptom scores use different trial scales; management said symptom improvement continued beyond six months and aims to emphasize clearance of disease-driving cells after launch.

  • Switch Study results in patients moving from avapritinib to bezuclastinib were expected at ASH in the coming weeks, with the study designed to assess symptom outcomes after switching.

  • Launch focus will include patients dissatisfied with or previously off Ayvakit; management expects hematologists to manage monitoring and treatment, with physician experience and patient advocacy supporting adoption.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Cogent Biosciences